↓ Skip to main content

BAFF- and APRIL-targeted therapy in systemic autoimmune diseases

Overview of attention for article published in Inflammation and Regeneration, July 2016
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
48 Dimensions

Readers on

mendeley
44 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
BAFF- and APRIL-targeted therapy in systemic autoimmune diseases
Published in
Inflammation and Regeneration, July 2016
DOI 10.1186/s41232-016-0015-4
Pubmed ID
Authors

Shingo Nakayamada, Yoshiya Tanaka

Abstract

B cells play a pivotal role in autoimmunity not only by producing pathogenic autoantibodies but also by modulating immune responses via the production of cytokines and chemokines. The B cell-activating factor/a proliferation-inducing ligand (BAFF/APRIL) system promotes B cell survival and differentiation and thus plays a prominent role in the pathogenesis of autoimmune diseases. Currently, BAFF and APRIL inhibitors are in clinical trials for systemic lupus erythematosus with significant efficacy. However, several studies have demonstrated the efficacy of the BAFF/APRIL blockade which showed considerable variability in the response to B cell-targeted therapy. This may indicate substantial heterogeneity in the pathogenesis of autoimmune diseases. Therefore, objective markers that can predict the effect of BAFF/APRIL-blocking agents could be valuable to the precision medicine linked clinically and to cost-effective therapy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 44 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 11 25%
Researcher 10 23%
Other 4 9%
Student > Postgraduate 3 7%
Student > Doctoral Student 2 5%
Other 5 11%
Unknown 9 20%
Readers by discipline Count As %
Medicine and Dentistry 11 25%
Immunology and Microbiology 6 14%
Biochemistry, Genetics and Molecular Biology 5 11%
Economics, Econometrics and Finance 3 7%
Agricultural and Biological Sciences 2 5%
Other 6 14%
Unknown 11 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 December 2017.
All research outputs
#17,285,036
of 25,373,627 outputs
Outputs from Inflammation and Regeneration
#163
of 258 outputs
Outputs of similar age
#249,433
of 378,809 outputs
Outputs of similar age from Inflammation and Regeneration
#4
of 4 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 258 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 378,809 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.